Stylized illustration of a heart intertwined with currency symbols and circuitry, representing heart health, technology, and healthcare costs.

Heart Failure Tech: Can New Devices Cut Your Healthcare Costs?

Lena Kashyap in Health & Wellness November 2025 • 3 min read.

"Innovative heart devices like MultiPoint Pacing (MPP) show promise in reducing hospital visits and saving you money. Is this the future of heart failure treatment?"

Heart failure is a serious condition, but technological advancements are offering new hope. MultiPoint Pacing (MPP) is one such innovation. This technology aims to improve cardiac resynchronization therapy (CRT), a treatment used to help the heart's chambers beat in a coordinated way.

Traditional CRT uses a quadripolar biventricular pacing (QUAD-BiV) system. MPP, however, offers a different approach by pacing from multiple points in the heart. Early studies suggest that MPP, particularly when configured for anatomically distant pacing (MPP-AS), may lead to better patient outcomes. This article explores whether MPP-AS can reduce healthcare costs associated with heart failure.

We'll delve into the findings of a study presented at the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA), which investigated the potential cost savings of MPP-AS compared to QUAD-BiV. The goal is to understand how these technologies impact hospitalization rates, emergency room visits, and overall healthcare expenses for heart failure patients.

MPP-AS: A Cost-Effective Solution for Heart Failure?

Stylized illustration of a heart intertwined with currency symbols and circuitry, representing heart health, technology, and healthcare costs.

The study used a model to simulate the costs associated with both MPP-AS and QUAD-BiV over a 10-year period. Researchers looked at various factors, including:

The study considered data from the MPP IDE trial, which included 52 patients programmed with MPP-AS and 232 with QUAD-BiV. This data provided the basis for estimating healthcare utilization rates for both groups.

Heart failure-related hospitalizations
Emergency room visits
Outpatient visits
Office visits
Mortality rates

The model then assigned costs to each type of healthcare event using data from the Marketscan Database, updated to reflect 2017 prices. By combining the utilization rates with the cost data, the researchers were able to estimate the total healthcare costs for each treatment strategy.

The Future of Heart Failure Treatment Costs

While the study suggests that MPP-AS may offer cost savings compared to QUAD-BiV, it’s important to note that these findings are based on a simulation model. More research is needed to confirm these results in real-world clinical settings. However, the study highlights the potential for innovative technologies like MPP-AS to not only improve patient outcomes but also reduce the financial burden of heart failure.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

How does MultiPoint Pacing (MPP) differ from traditional cardiac resynchronization therapy (CRT) using a quadripolar biventricular pacing (QUAD-BiV) system?

MultiPoint Pacing (MPP), particularly when configured for anatomically distant pacing (MPP-AS), is designed to improve cardiac resynchronization therapy (CRT). Unlike traditional CRT, which typically uses a quadripolar biventricular pacing (QUAD-BiV) system, MPP paces from multiple points in the heart. The intent is to achieve more coordinated heart chamber contractions and, potentially, better patient outcomes. The critical difference lies in the pacing strategy; MPP offers a more targeted approach compared to the broader stimulation provided by QUAD-BiV.

What methodology was employed to assess the cost-effectiveness of MultiPoint Pacing configured for anatomically distant pacing (MPP-AS) compared to quadripolar biventricular pacing (QUAD-BiV) in heart failure treatment?

A study presented at the 22nd Annual Scientific Meeting of the Heart Failure Society of America (HFSA) used a simulation model to compare the costs associated with MultiPoint Pacing configured for anatomically distant pacing (MPP-AS) and quadripolar biventricular pacing (QUAD-BiV) over a 10-year period. Researchers considered factors such as heart failure-related hospitalizations, emergency room visits, outpatient visits, office visits, and mortality rates. They combined healthcare utilization rates from the MPP IDE trial with cost data from the Marketscan Database to estimate total healthcare costs for each treatment strategy. These simulations are essential to understanding the financial implications of adopting new medical technologies.

Based on the study, what are the potential cost savings associated with MultiPoint Pacing configured for anatomically distant pacing (MPP-AS) compared to quadripolar biventricular pacing (QUAD-BiV)?

The study suggested that MultiPoint Pacing configured for anatomically distant pacing (MPP-AS) may offer cost savings compared to quadripolar biventricular pacing (QUAD-BiV). This conclusion was based on a simulation model that projected healthcare costs over a 10-year period, considering factors like hospitalizations and emergency room visits. However, it's crucial to remember that these findings are preliminary and based on a model, further research in real-world clinical settings is needed to validate these potential cost savings. The model does not take into account factors outside of the clinical trial, such as the success rate of the procedures at individual hospitals.

What role did the MPP IDE trial play in estimating the potential cost savings of MultiPoint Pacing configured for anatomically distant pacing (MPP-AS)?

The MPP IDE trial provided data on 52 patients programmed with MultiPoint Pacing configured for anatomically distant pacing (MPP-AS) and 232 patients with quadripolar biventricular pacing (QUAD-BiV). This data informed the healthcare utilization rates used in the cost simulation model. The trial serves as a foundation for estimating the potential economic benefits of MPP-AS; however, its limitations, such as sample size and specific patient characteristics, should be considered when interpreting the findings. Larger, more diverse studies are needed to confirm these results.

What is the significance of cardiac resynchronization therapy (CRT), and how does MultiPoint Pacing (MPP) contribute to advancements in this treatment for heart failure?

Cardiac resynchronization therapy (CRT) is a treatment designed to help the heart's chambers beat in a coordinated manner, typically using a quadripolar biventricular pacing (QUAD-BiV) system. MultiPoint Pacing (MPP), particularly with anatomically distant pacing (MPP-AS), is an advancement that aims to improve upon traditional CRT by pacing from multiple points in the heart. Ideally, this coordinated pacing improves the heart's efficiency and reduces symptoms of heart failure. If further studies confirm cost savings, this could lead to increased access to this advanced therapy, improving outcomes for a larger number of heart failure patients.